Cargando…

Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis

We tested the hypothesis that bevacizumab-induced hypertension may be a useful predictor for objective response rate, progression-free and overall survival in patients with metastatic colorectal cancer via a comprehensive meta-analysis. Search process, article selection and data extraction were inde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chun-Jing, Zhang, Shu-Ying, Zhang, Chun-Di, Lin, Chun-Rong, Li, Xue-Yan, Li, Qiu-Yan, Yu, Hai-Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046235/ https://www.ncbi.nlm.nih.gov/pubmed/29969436 http://dx.doi.org/10.18632/aging.101478

Ejemplares similares

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer
por: Zhu, Yan-Juan, et al.
Publicado: (2017)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis
por: Zhang, Li, et al.
Publicado: (2020)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
por: Li, Ching-Chun, et al.
Publicado: (2018)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
por: Feliu, Jaime, et al.
Publicado: (2015)

Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer
por: Dionísio de Sousa, Isabel José, et al.
Publicado: (2016)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials
por: Zhu, Xiaoqiang, et al.
Publicado: (2016)

A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
por: Bai, Long, et al.
Publicado: (2015)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
por: You, Xia-Hong, et al.
Publicado: (2019)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis()
por: Quan, Qi, et al.
Publicado: (2017)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022)

Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis
por: Wang, Chun, et al.
Publicado: (2019)

The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer
por: Zhang, Chi-Hao, et al.
Publicado: (2018)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
por: He, Ying, et al.
Publicado: (2022)

Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
por: Huang, Yuanyuan, et al.
Publicado: (2019)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
por: Guan, Zhong-Zhen, et al.
Publicado: (2011)

MicroRNA-155 enhances the activation of Wnt/β-catenin signaling in colorectal carcinoma by suppressing HMG-box transcription factor 1
por: Wan, Ying-Chun, et al.
Publicado: (2022)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis
por: Cao, Dedong, et al.
Publicado: (2019)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2014)

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)
por: Zinser-Sierra, Juan W., et al.
Publicado: (2012)

Increased mortality for colorectal cancer patients with preexisting diabetes mellitus: an updated meta-analysis
por: Li, Jingtao, et al.
Publicado: (2017)

Expert consensus on maintenance treatment for metastatic colorectal cancer in China
por: Xu, Rui-Hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aos21onrgtnh4sdslujm9cdpk8